



Arsenal Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

South San Francisco, Calif. – January 2, 2024 – Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company engineering advanced CAR T-cell therapies for solid tumors, today announced that Ken Drazan, MD, the company’s Chairman and Chief Executive Officer, will present a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 9:30 am PT.

About ArsenalBio

Arsenal Biosciences, Inc. (ArsenalBio), headquartered in South San Francisco, Calif., is a clinical stage programmable cell therapy company discovering and developing a pipeline of next-generation autologous T cell therapies to defeat cancer. Our full-stack R&D engine generates multifunctional T cell medicines, enabled by precise and specific CRISPR-mediated insertion of large synthetic DNA cassettes. ArsenalBio is building the industry’s largest DNA library of potential therapeutic enhancing integrated circuits, incorporating logic gating for improved tumor targeting and synthetic features enabling multiple pharmaceutical functions. In pioneering a computationally driven approach alongside nonviral clinical manufacturing, we aspire to deliver enhanced efficacy, increased patient safety, reduced stakeholder costs, and expanded market access. To learn more, visit www.arsenalbio.com and follow us on Twitter [@ArsenalBio](https://twitter.com/ArsenalBio), [LinkedIn](https://www.linkedin.com/company/arsenalbio) and [Facebook](https://www.facebook.com/arsenalbio).

Media Contacts:

Gwen Gordon
858-245-5684
gwen@gwengordonpr.com